The present invention discloses a DBN based separation method of a mixture of dual-tracer single-acquisition PET signals labelled with the same isotope. It predicts the two separate PET signals by establishing a complex mapping relationship between the dynamic mixed concentration distribution of the same isotope-labeled dual-tracer pairs and the two single radiotracer concentration images. Based on the compartment models and the Monte Carlo simulation, the present invention selects three sets of the same radionuclide-labeled tracer pairs as the objects and simulates the entire PET process from injection to scanning to generate enough training sets and testing sets. When inputting the testing sets into the constructed universal deep belief network trained by the training sets, the prediction results show that the two individual PET signals can been reconstructed well, which verifies the effectiveness of using the deep belief network to separate the dual-tracer PET signals labelled with the same isotope.

Described herein are bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.

Surrogate materials are in the form of solid particles that include surrogate isotopes, namely, short-lived isotopes selected and formed to serve as surrogates for the radioactive materials of a nuclear fallout without including isotopes that are, or that decay to, biologically or environmentally deleterious and persistent isotopes. The surrogate material may be formed using high-purity reactant material and irradiation and separation techniques that enable tailoring of the isotopes and ratios thereof included in the surrogate material, and the surrogate material may be dispersed, e.g., in a training environment, in solid form.

A modular radio-labeling tracer synthesizer system comprising a housing having a plurality of slots containing syringe actuators. Each syringe actuator including a syringe holder, a syringe driver for driving a syringe plunger in a loading and/or dispensing direction. The unit is capable of adopting multiple configurations and is fully programmable and provides enhanced flexibility in development of novel radiotracers.

A modular radio-labeling tracer synthesizer system comprising a housing having a plurality of slots containing syringe actuators. Each syringe actuator including a syringe holder, a syringe driver for driving a syringe plunger in a loading and/or dispensing direction. The unit is capable of adopting multiple configurations and is fully programmable and provides enhanced flexibility in development of novel radiotracers.

Multiphase microspheres for radioembolization include two-phase microspheres and three-phase microspheres prepared by a microfluidic process. The multiphase microspheres include a primary phase and a first secondary phase surrounded by the primary phase. The primary phase includes a first resin. The first secondary phase includes a second resin and at least one of a radioactive isotope or a compound including at least one radioactive element. Three-phase microspheres additionally include a second secondary phase discrete from the first secondary phase and also surrounded by the primary phase. The second secondary phase may be a gas such as air. The microspheres may be formed by a microfluidic process.

An infusion system may include a radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to calibrate the infusion system using the gamma detector. For example, the controller may generate a radioactive eluate and measure the activity of the radioactive eluate using both the beta detector and the gamma detector. The high accuracy of the activity measured by the gamma detector may be used to calibrate the infusion system. In subsequent use, the infusion system calibrated using the gamma detector may adjust measurements made to monitor and/or control patient infusion procedures.

An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

A tagged excavation element, including an excavation element body and a tagging device securable to the excavation element body. The tagged excavation element is characterized in that the tagging device includes a man-made radioactive source. Typically, but not exclusively, the excavation element body comprises a shroud or tooth of an excavation bucket of a ground excavation tool (GET). A method is provided for manufacturing the tagged excavation element, and for detecting the tagged excavation element.